Financial Performance - The company reported revenue of RMB 700.7 million for the six months ended June 30, 2023, representing a 21.2% increase from RMB 577.9 million in the same period of 2022[19]. - The net profit for the company was RMB 110.4 million, compared to a net loss of RMB 53.3 million in the same period of 2022, marking a significant turnaround[19]. - Basic earnings per share increased to RMB 0.75, compared to a basic loss per share of RMB 0.54 in the same period of 2022[19]. - The gross profit for the six months ended June 30, 2023, was RMB 355.6 million, reflecting a 26.5% increase from the previous year[20]. - The company's other income and gains rose from RMB 13.9 million to RMB 21.8 million, mainly due to foreign exchange gains of RMB 7.3 million in the first half of 2023 compared to a loss of RMB 84.6 million in the same period of 2022[36]. - The company reported a total comprehensive income of RMB 147,170 thousand for the period, compared to a loss of RMB 65,286 thousand in the same period last year[85]. - The company reported a net cash flow from operating activities of RMB 111,187,000 for the six months ended June 30, 2023, compared to RMB 75,268,000 for the same period in 2022, representing a year-over-year increase of about 47.8%[92]. - The company reported a pre-tax profit of RMB 142,229,000 for the six months ended June 30, 2023, compared to a loss of RMB 32,147,000 in the same period of 2022[114]. Research and Development - Research and development expenses were RMB 26.1 million, up 16.5% from RMB 22.4 million in the same period of 2022, maintaining a stable ratio of approximately 3.7% of revenue[19]. - The company has established a "global 4+2" R&D layout with seven R&D and production platforms in China and two overseas in the Netherlands and Germany[20]. - The company continues to invest in R&D and has appointed Dr. Alexey Nikolaevich Simonov as the Chief Technology Officer[20]. - R&D expenditure was RMB 26.1 million, accounting for 3.7% of total revenue, a 16.5% increase from RMB 22.4 million in the same period last year[26]. - The company aims to enhance its proprietary product revenue share and increase investment in surgical treatment products while maintaining its leading position in diagnostic products[29]. - The company is advancing the registration of the new generation ATOS femtosecond corneal refractive surgery system and the ANTERION multimodal imaging platform[28]. - The company has invested 10 million euros in R&D for the development of innovative glaucoma treatments[151]. Sales and Market Presence - Sales of proprietary products reached RMB 193.9 million, accounting for 32.7% of total product sales, setting a new record[20]. - Revenue from proprietary products reached RMB 193.9 million, accounting for 32.7% of total sales, a 36.5% increase from RMB 142.0 million in the same period last year[23]. - Revenue from distribution products was RMB 399.4 million, representing 67.3% of total sales, up 17.9% from RMB 338.7 million year-over-year[24]. - The company serves over 4,000 end customers in China, including more than 1,200 tertiary hospitals and 1,500 secondary hospitals[20]. - The company has partnered with 19 overseas brand partners, with 17 having exclusive distribution agreements, including two new partners added during the reporting period[20]. - The company is expanding its market presence in Asia, targeting a 25% increase in market share by the end of 2024[151]. Expenses and Costs - Selling and distribution expenses increased by 34.2% to RMB 120.9 million, representing 17.3% of revenue, up from 15.6% in the previous year[37]. - Administrative expenses decreased by 10.5% to RMB 62.5 million, primarily due to the absence of listing expenses incurred in the previous year[38]. - Financing costs slightly increased from RMB 20.7 million to RMB 23.7 million, attributed to higher interest expenses on domestic loans and preferred financing loans[39]. - The cost of goods sold increased to RMB 345,096,000, up from RMB 296,633,000, representing a growth of approximately 16.3% year-over-year[106]. - Employee benefits expenses amounted to RMB 48,467,000 for the six months ended June 30, 2023, compared to RMB 44,297,000 for the same period in 2022, reflecting an increase of about 4.9%[107]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 1,969,859 thousand, an increase from RMB 2,225,467 thousand as of December 31, 2022[86]. - Current liabilities increased to RMB 878,342 thousand from RMB 492,623 thousand at the end of the previous year[86]. - Cash and cash equivalents decreased by 10.9% from RMB 721.5 million as of December 31, 2022, to RMB 642.5 million as of June 30, 2023, due to the use of operating surplus funds for investments in financial assets[55]. - Trade receivables decreased from RMB 166.4 million as of December 31, 2022, to RMB 158.9 million as of June 30, 2023, due to improved collection management[49]. - Trade payables increased from RMB 68.7 million as of December 31, 2022, to RMB 96.6 million as of June 30, 2023, primarily due to preemptive stockpiling after the lifting of pandemic control measures[50]. - The debt-to-asset ratio improved from 50.9% as of December 31, 2022, to 46.1% as of June 30, 2023[57]. Corporate Governance and Management - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with applicable corporate governance codes[64]. - The company has adopted a code of conduct for securities trading, ensuring all directors complied with the standards during the reporting period[65]. - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2023[66]. - The company has no other disclosure obligations under the Listing Rules apart from what is disclosed in the interim report[79]. - The company has maintained a stable relationship with its related parties, with minimal transactions reported in the current period compared to the previous year[137]. Future Outlook - The company plans to focus on obtaining regulatory approvals for new products and expanding its market presence in the second half of 2023[30]. - The company aims to leverage its product line and brand advantages to ensure favorable bidding outcomes for its ophthalmic products[30]. - The company plans to increase its workforce by 15% to support its expansion and R&D efforts[151]. - A strategic acquisition of a technology firm is anticipated to enhance the company's R&D capabilities and product offerings[150].

[41 -> 70] 各位参议师以及投资者朋友们,大家上午好。欢迎各位出席高市医疗2023年度中期业绩发布会。首先,我们有请田圆女士做开场介绍。大家好,欢迎各位参会。首先介绍一下,参加本次发布会的公司管理层代表有高市医疗创始人、董事长兼首席执行官高铁塔先生、联席CEO兼执行董事刘新伟先生、 [70 -> 96] 以及首席财务官执行董事,尽涉及内在风险及不确定因素,可能导致实际业绩偏离当前的预期。有关该等风险及不确定因素的详细论述,请参阅高市医疗向香港交易所递交的最新公告内容。 [96 -> 126] 本次会议中所提供的一切紧张性陈述均基于我们认为截至今日合理的假设高市医疗并不承担更新该等陈述的任何义务除非适用法律另有规定本次讨论还包含某些非国际财务报告准则的财务措施仅供比较之用稍后刘兴伟先生将首先向大家介绍高市医疗的业务发展情况及未来展望第二部分由李文琪女士帮我们回顾公司的财务表现 [126 -> 156] 在管理层的讲解之后 在管理层的讲解之后 我们将会举行一个简单的问答环节 我们将会举行一个简单的问答环节 各位如需与管理层进行线上提问 各位如需与管理层进行线上提问 可通过举手语音提问或文字提问 可通过举手 ...

Financial Performance - For the six months ended June 30, 2023, the company recorded revenue of RMB 700.7 million, an increase of 21.2% compared to RMB 577.9 million for the same period in 2022[2]. - The net profit for the six months ended June 30, 2023, was RMB 110.4 million, a significant recovery from a net loss of RMB 53.3 million in the same period of 2022, and an increase of 22.0% compared to the adjusted net profit of RMB 90.5 million for 2022[2][5]. - The gross profit for the six months ended June 30, 2023, was RMB 355.6 million, representing a 26.5% increase from RMB 281.2 million in the previous year[5]. - Total revenue for the six months ended June 30, 2023, was RMB 700.7 million, a 21.2% increase from RMB 577.9 million for the same period in 2022[17]. - Gross profit increased by 26.5% to RMB 355.6 million, with a gross margin improvement from 48.7% to 50.8%[19]. - The total comprehensive income for the period was RMB 147,170 thousand, compared to a loss of RMB 65,286 thousand in the previous year[60]. - The net profit attributable to the owners of the parent company for the period was RMB 110,421 thousand, compared to a loss of RMB 53,264 thousand in the previous year[57]. - Basic earnings per share for the period was RMB 0.75, a recovery from a loss of RMB 0.54 per share in the prior year[57]. Research and Development - Research and development expenses amounted to RMB 26.1 million, up 16.5% from RMB 22.4 million in the same period of 2022, maintaining a stable ratio of approximately 3.7% of revenue[2][3]. - The company has established a "global 4+2" R&D layout with seven R&D and production platforms in China and two overseas in the Netherlands and Germany, covering sales in 51 countries and regions[4]. - The group aims to enhance its product line through mergers and acquisitions while increasing R&D investment to boost the proportion of self-owned product revenue[14]. - The group has established a "global 4+2" R&D layout with 211 R&D personnel, averaging over ten years of industry experience, and production facilities exceeding 14,000 square meters[11]. - The company plans to invest €10 million in research and development over the next year to innovate new technologies[101]. Product Revenue - Revenue from proprietary products reached RMB 193.9 million, accounting for 32.7% of total product sales, a 36.5% increase from RMB 142.0 million in the same period of 2022[8]. - Revenue from distribution products contributed RMB 399.4 million, representing 67.3% of total product sales, an increase of 17.9% from RMB 338.7 million in the previous year[9]. - Revenue from self-owned products was RMB 193,868,000, up from RMB 141,991,000, representing a 36.5% increase year-over-year[70]. - Sales of ophthalmic medical devices contributed RMB 337.9 million, up from RMB 274.5 million, with a gross margin of 48.7%[20]. Expenses and Costs - Selling and distribution expenses increased by 34.2% to RMB 120.9 million, representing 17.3% of total revenue, up from 15.6%[22]. - Administrative expenses decreased by 10.5% to RMB 62.5 million, attributed to the absence of listing expenses following the company's IPO[23]. - The total employee cost for the six months ended June 30, 2023, was RMB 169.6 million, compared to RMB 143.8 million for the same period in 2022[47]. - Financing costs increased slightly to RMB 23.7 million due to higher interest expenses on domestic loans and preferred financing loans[24]. Assets and Liabilities - As of June 30, 2023, the company's cash and cash equivalents amounted to RMB 642.5 million, a decrease of 10.9% from RMB 721.5 million as of December 31, 2022[40]. - Total liabilities increased significantly to RMB 1,212,798 thousand, up 56.5% from RMB 792,405 thousand as of December 31, 2022[64]. - The debt-to-asset ratio as of June 30, 2023, was 46.1%, down from 50.9% as of December 31, 2022[43]. - Trade receivables decreased from RMB 166.4 million as of December 31, 2022, to RMB 158.9 million as of June 30, 2023, due to improved collection management[34]. - Inventory increased from RMB 281.1 million as of December 31, 2022, to RMB 305.3 million as of June 30, 2023, reflecting changes in finished goods based on sales plans[33]. Market and Strategic Initiatives - The company has partnered with 19 overseas brands, with 17 having exclusive distribution agreements, including two new partners added during the reporting period[4][9]. - The company is focusing on maximizing operational efficiency and expanding market space in the second half of 2023, with specific attention to the registration progress of RGP products and the new generation navigation femtosecond refractive surgery system ATOS[15]. - The company plans to expand its market presence and enhance product offerings through ongoing research and development initiatives[99]. - The company is expanding its market presence in Europe, targeting a 25% increase in market share by the end of 2024[102]. Taxation - The company has maintained a favorable tax rate of 15% for its subsidiary recognized as a "High-tech Enterprise" in China, compared to the standard rate of 25%[79]. - The total tax expense for the six months ended June 30, 2023, was RMB 31,808,000, compared to RMB 21,117,000 for the same period in 2022, representing a 50.3% increase[81]. - The company anticipates that the tax deduction rate for R&D expenses will be increased to 100% starting from January 1, 2023, which may positively impact future profitability[83]. Corporate Governance - The company has adopted a corporate governance code to ensure accountability and protect shareholder interests, although the roles of Chairman and CEO are held by the same individual[52]. - The audit committee has reviewed the interim financial statements, confirming compliance with applicable accounting standards and regulations[54].

Financial Performance - Revenue for 2022 was RMB 1,253.8 million, a decrease of 3.4% compared to RMB 1,298.2 million in 2021[6] - Net loss for 2022 was RMB 352.7 million, an increase of 84.1% compared to RMB 191.6 million in 2021[6] - Adjusted net profit (non-IFRS measure) for 2022 was RMB 157.3 million, a decrease of 8.2% compared to RMB 171.3 million in 2021[6] - Basic loss per share for 2022 was RMB 3.61, an increase of 81.4% compared to RMB 1.99 in 2021[6] - Revenue for 2022 was RMB 1,253.8 million, a decrease of 3.4% compared to the previous year[11] - Gross profit increased to RMB 625.3 million in 2022, up by 2.6% year-over-year[11] - Sales of ophthalmic medical equipment decreased to RMB 641.3 million in 2022 from RMB 718.7 million in 2021[12] - Sales of ophthalmic medical consumables increased to RMB 411.8 million in 2022 from RMB 408.4 million in 2021[12] - Technical service revenue rose to RMB 190.1 million in 2022 from RMB 161.6 million in 2021[12] - Revenue decreased by 3.4% from RMB 1,298.2 million in 2021 to RMB 1,253.8 million in 2022 due to the impact of COVID-19, particularly in December 2022[24][26] - Sales of ophthalmic medical equipment decreased by RMB 77.4 million, partially offset by an increase in technical service revenue of RMB 28.5 million and ophthalmic medical consumables revenue of RMB 3.4 million[26] - Gross profit increased by 2.6% to RMB 625.3 million in 2022, with gross margin improving from 46.9% in 2021 to 49.9% in 2022[29] - Gross margin for ophthalmic medical consumables increased to 55.6% in 2022 from 51.2% in 2021, while gross margin for technical services rose to 48.0% from 43.4%[30] - Sales and distribution expenses decreased slightly by 0.9% to RMB 187.8 million in 2022, accounting for 15.0% of revenue compared to 14.6% in 2021[32] - Administrative expenses increased by 11.2% to RMB 146.2 million in 2022, driven by higher personnel costs and listing-related expenses[33] - Other income and gains decreased significantly to RMB 21.1 million in 2022 from RMB 77.9 million in 2021, mainly due to foreign exchange losses of RMB 172.5 million[31] - Financing costs decreased by 48.9% from RMB 83.5 million in 2021 to RMB 42.7 million in 2022, primarily due to the repayment of interest-bearing loans[34] - R&D costs increased by 74.8% from RMB 23.5 million in 2021 to RMB 41.1 million in 2022, driven by team expansion and R&D center upgrades[35] - The fair value loss on convertible redeemable preferred shares decreased from RMB 375.6 million in 2021 to RMB 307.4 million in 2022 due to changes in the company's valuation[36] - Other expenses surged from RMB 21.7 million in 2021 to RMB 196.4 million in 2022, mainly due to increased exchange losses on preferred shares[36] - Income tax expenses rose by 44.8% from RMB 53.6 million in 2021 to RMB 77.6 million in 2022, reflecting higher taxable profits[37] - The company recorded a net loss of RMB 352.7 million in 2022, compared to a net loss of RMB 191.6 million in 2021[38] - Adjusted net profit (non-IFRS) decreased by 8.2% from RMB 171.3 million in 2021 to RMB 157.3 million in 2022, impacted by pandemic control policies and increased R&D expenses[39] - Inventory increased by 17.1% from RMB 240.1 million in 2021 to RMB 281.1 million in 2022, with inventory turnover days rising from 129 days to 155 days[41] - Trade receivables decreased by 4.7% from RMB 180.2 million in 2021 to RMB 171.7 million in 2022, with turnover days remaining stable at 50-51 days[42] - Goodwill increased by 2.7% from RMB 882.7 million in 2021 to RMB 906.9 million in 2022, mainly due to exchange rate fluctuations between RMB and EUR[45] - Intangible assets decreased by 8.2% from RMB 303.9 million as of December 31, 2021, to RMB 278.9 million as of December 31, 2022, primarily due to accumulated amortization[46] - Cash and cash equivalents increased by 18.5% from RMB 609.0 million as of December 31, 2021, to RMB 721.5 million as of December 31, 2022, driven by IPO proceeds and increased operating cash flow[47] - Capital expenditures increased by 71.2% from RMB 28.0 million in 2021 to RMB 48.0 million in 2022, mainly for production-related equipment and daily renovation expenses[49] - The asset-liability ratio improved to 50.9% as of December 31, 2022, compared to a negative 151.8% as of December 31, 2021, due to the elimination of net liabilities under IFRS[50] - The company repaid a total of EUR 11.25 million of long-term loans from Swiss banks and EUR 25.0 million of mezzanine financing loans in 2022[47] - The effective annual interest rate for bank and other borrowings ranged from 1.50% to 7.00% as of December 31, 2022, with remaining loan terms ranging from less than one year to three years[48] - The company recorded a foreign exchange gain of RMB 24.5 million in 2022, compared to a loss of RMB 58.6 million in 2021, due to fluctuations in the Euro exchange rate[52] - The company has no significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures as of December 31, 2022[54] - The company has no significant future plans for investments or capital assets beyond those disclosed in the annual report and prospectus[55] - The company maintains a robust liquidity position with sufficient cash and bank balances to meet operational needs and support expansion plans[47] - The company's global offering generated net proceeds of approximately HKD 284.71 million after deducting underwriting fees, commissions, and other estimated expenses[78] - Net proceeds of HKD 284.71 million were utilized as of December 31, 2022, with HKD 216.27 million remaining unused[80] - 38.2% of net proceeds (HKD 108.76 million) allocated to R&D and patent commercialization, expected to be fully utilized by December 11, 2024[80] - 29.0% of net proceeds (HKD 82.56 million) allocated to capacity expansion and manufacturing enhancement, expected to be fully utilized by December 11, 2024[80] - 9.5% of net proceeds (HKD 27.05 million) allocated to sales and marketing expansion, expected to be fully utilized by December 11, 2024[80] - 10.6% of net proceeds (HKD 30.18 million) allocated to working capital and general corporate purposes[80] - 12.7% of net proceeds (HKD 36.16 million) allocated to repayment of interest-bearing borrowings[80] - Additional net proceeds of HKD 1.77 million were generated from the partial exercise of the over-allotment option on January 9, 2023[81] - The company had distributable reserves of approximately RMB 822.2 million as of December 31, 2022[87] - The company had a total of 790 employees as of December 31, 2022, with total employee costs amounting to RMB 288.4 million for the year[94] - The company's core values emphasize employee development, with a focus on training and skill enhancement across various levels and positions[94] - The company operates a defined contribution retirement plan, with contributions made based on a percentage of employee salary costs[95] - Liu Xinwei was appointed as Co-CEO and his annual salary was adjusted from RMB 1,070,000 to RMB 1,170,000 effective January 10, 2023[96] - Zhang Jianjun resigned as President and was appointed as Honorary President, with his annual salary adjusted from RMB 1,160,000 to RMB 800,000 effective January 10, 2023[96] - Gao Tieta holds a 42.76% stake in the company through controlled corporate interests, owning 63,263,528 shares[98] - Zhang Jianjun holds a 4.81% stake in the company through controlled corporate interests, owning 7,112,360 shares[98] - Zhao Xinli holds a 2.32% stake in the company through controlled corporate interests, owning 3,436,116 shares[98] - Liu Xinwei holds a 0.65% stake in the company through controlled corporate interests, owning 955,879 shares[98] - No directors or senior executives have rights to acquire shares or debentures of the company or any other corporate body as of December 31, 2022[100] - GT HoldCo holds 63,263,528 shares, representing 42.76% of the company's issued share capital[102] - OrbiMed Asia directly holds 18,039,426 shares, representing 12.19% of the issued share capital[103] - Cuprite Gem directly holds 11,375,840 shares, representing 7.69% of the issued share capital[104] - GT HoldCo had 38,472,296 shares mortgaged to Credit Suisse for a HKD 185,000,000 loan, which was fully repaid by April 6, 2023[103] - The company has no significant legal proceedings or claims pending or threatened against it as of December 31, 2022[109] - The company maintains a minimum public float of 25% of its total issued share capital, as required by the Hong Kong Stock Exchange[111] - Ernst & Young was appointed as the auditor for the fiscal year ending December 31, 2022, and will be proposed for re-election at the upcoming annual general meeting[112] - The company has adopted the Corporate Governance Code as its own governance standard and has complied with all applicable code provisions during the reporting period[114] - The company emphasizes a culture of integrity, ethical behavior, and compliance, with standards integrated into employee training materials and policies such as the Code of Conduct and Anti-Corruption Policy[116] - The company is committed to employee development, workplace safety, diversity, and sustainability, aiming for long-term, stable, and sustainable growth[117] - The Board of Directors consists of 4 executive directors, 2 non-executive directors, and 3 independent non-executive directors, with one independent director possessing appropriate professional qualifications in accounting or financial management[119] - Independent non-executive directors play a crucial role in providing impartial views on strategy, performance, and controls, ensuring shareholder interests are considered[121] - The company has adopted a Board Diversity Policy to enhance efficiency and maintain high governance standards, considering factors such as gender, age, cultural background, and professional experience[122] - The Board's current composition includes directors with diverse expertise in medicine, business administration, finance, and accounting, aged between 41 and 62[122] - The company has implemented a Board Independence Evaluation Mechanism to ensure strong independent elements and effective decision-making[121] - The company has arranged appropriate liability insurance for directors, with coverage reviewed annually[118] - The Board has delegated specific oversight responsibilities to three committees: Audit, Remuneration, and Nomination Committees[118] - The company aims to appoint at least one female director within one year of the listing date and achieve a target of no less than 20% female representation on the board within five years, subject to satisfaction of candidates' qualifications and experience[123] - As of December 31, 2022, the company had 790 full-time employees, with female employees accounting for approximately 36.7% of the workforce, achieving a relatively balanced gender ratio[123] - The company has set measurable goals, including having at least one female member in the senior management team and maintaining at least 35% female representation among full-time employees[123] - Li Wenqi, a female executive, was appointed as the company's CFO in January 2023, responsible for the group's overall financial management[123] - The company provides necessary induction training and regular updates to newly appointed directors to ensure they are well-informed about the company's operations and regulatory responsibilities[124] - Directors are encouraged to participate in continuous professional development programs to enhance their knowledge and skills, with external legal counsel providing training on regulatory updates[124] - The Chairman and CEO roles are held by the same individual, Gao Tieta, due to his extensive experience and understanding of the company's business, which facilitates strategic execution and information flow[126] - The company's board consists of experienced and talented individuals, with decisions requiring approval by at least a majority of the directors, ensuring checks and balances[126] - Executive and non-executive directors have service contracts with the company, initially for three years from the listing date, renewable under applicable laws and regulations[127] - Independent non-executive directors have appointment letters with the company, also initially for three years from the listing date, renewable under applicable laws and regulations[127] - The company will hold at least four regular board meetings in the fiscal year ending December 31, 2023[128] - The board chairman will hold at least one meeting with independent non-executive directors without the presence of other directors in the fiscal year ending December 31, 2023[128] - The audit committee reviewed the audited consolidated financial statements and annual results for the year ended December 31, 2022, during its meeting on March 31, 2023[133] - The audit committee also reviewed the effectiveness of the company's financial reporting, risk management, and internal control systems during the March 31, 2023 meeting[133] - The nomination committee is responsible for reviewing the board's structure, size, and composition at least annually and making recommendations for changes to align with the company's corporate strategy[134] - The nomination committee is tasked with identifying and evaluating candidates for board and senior management positions, including assessing the balance of skills, knowledge, and experience on the board[134] - The board retains decision-making authority over all significant matters, including policy approval, overall strategy, budgets, internal controls, risk management systems, and major transactions[130] - The company has adopted a code of conduct for securities transactions by directors and employees, with terms no less stringent than the standard code[129] - The board is collectively responsible for corporate governance, including reviewing and monitoring compliance with legal and regulatory requirements[131] - The audit committee is responsible for overseeing the company's financial reporting system, risk management, and internal control systems[132] - The company held its first nomination committee meeting on March 31, 2023, where it reviewed the composition of the board and its committees, recommended the re-election of retiring directors, and proposed the appointment of Dr. Alexey Nikolaevich Simonov as Chief Technology Officer[135] - The nomination committee evaluates candidates based on diversity factors including gender, age, cultural and educational background, race, professional experience, skills, knowledge, and tenure, as well as their potential contributions to shareholder value[137] - The nomination process includes consulting various sources, assessing candidates through interviews and background checks, and making recommendations to the board, which has the final authority to appoint directors[138] - The remuneration committee reviewed and recommended the compensation for directors and senior management for the year ending December 31, 2023, including adjustments for some executive directors and senior management[140] - The company's director remuneration policy includes a fixed component (base salary) and a variable component (discretionary bonuses and other incentives), considering factors such as experience, responsibility level, individual performance, and market conditions[141] - The total remuneration for audit and non-audit services provided by the auditor in 2022 amounted to RMB 19,519 thousand, with audit services accounting for RMB 17,587 thousand and non-audit services for RMB 1,932 thousand[145] - The company has established a robust risk management and internal control system, which is reviewed annually by the Board to ensure effectiveness and compliance with legal and regulatory requirements[150] - The company has adopted an anti-corruption policy and a whistleblowing policy to promote ethical behavior, compliance, and good corporate governance, with no significant fraud or misconduct reported for the year 2022[147][148] - The company maintains a high level of corporate governance, with monthly updates provided to the Board on the group's performance, status, and prospects[144] - The company has implemented an insider information management system to ensure timely disclosure of material information and strict control over information dissemination[149] - The company's internal audit function plays a key role in monitoring internal governance, with findings reported to the Audit Committee and, if necessary, to the Board[149] - The company's risk management system includes clear division of responsibilities and authority, regular compliance training for employees, and mechanisms for identifying and mitigating potential risks[149] - The company's ESG-related resources, staff qualifications, training programs, and budgets are deemed sufficient by the Board, with ESG risks included in the risk management framework[150] - The company's corporate governance framework emphasizes high standards of integrity, transparency, and ethical business practices, supported by policies such as the anti-corruption and whistleblowing policies[146][147] - The company's financial statements for 2022 were prepared in accordance with applicable standards, with no significant uncertainties identified that could cast doubt on the group's ability to continue as a going concern[144] - The company has no specific dividend policy or predetermined payout ratio, and future dividend payments will be determined by the board based on profits, cash flow, financial condition, capital requirements, and other relevant factors[152] - The company held its IPO on December 12, 2022, and has not yet held an annual general meeting since listing[153] - The company has established multiple channels for shareholder communication, including annual reports, interim reports, circulars, regular announcements

Financial Performance - For the year ended December 31, 2022, the company's revenue was RMB 1,253.8 million, a decrease of 3.4% compared to RMB 1,298.2 million for the previous year[2]. - The company's net loss for the year ended December 31, 2022, was RMB 352.7 million, an increase of 84.1% from a net loss of RMB 191.6 million in the previous year[2]. - The adjusted net profit (non-IFRS) for the year ended December 31, 2022, was RMB 157.3 million, down 8.2% from RMB 171.3 million in the previous year[2]. - The gross profit for the year ended December 31, 2022, increased to RMB 625.3 million, a rise of 2.6% compared to RMB 609.5 million in the previous year[4]. - The company's revenue decreased by 3.4% from RMB 1,298.2 million in the year ended December 31, 2021, to RMB 1,253.8 million in the year ended December 31, 2022, primarily due to a reduction in sales of ophthalmic medical equipment[21]. - The sales revenue from agency products was RMB 744.8 million, down from RMB 811.0 million in 2021, while self-owned products generated RMB 308.3 million, slightly down from RMB 316.1 million in the previous year[22]. - The company's gross profit increased by 2.6% from RMB 609.5 million in 2021 to RMB 625.3 million in 2022, with the gross margin rising from 46.9% to 49.9%[24]. - The company's net loss for the year ended December 31, 2022, was RMB 3.527 billion, compared to a net loss of RMB 1.916 billion for the year ended December 31, 2021[36]. - Adjusted net profit (non-IFRS measure) decreased by 8.2% from RMB 1.713 billion for the year ended December 31, 2021, to RMB 1.573 billion for the year ended December 31, 2022, primarily due to the impact of COVID-19 control policies on revenue and increased R&D expenses[37]. Revenue Segmentation - The revenue contribution from self-owned products accounted for 29.3% of total sales, up from 28.0% in the previous year[8]. - The revenue from self-owned products and technical services reached historical highs of RMB 308.3 million and RMB 190.1 million, respectively[4]. - The self-owned product segment generated revenue of RMB 389,054 thousand, with a gross profit of RMB 186,599 thousand[79]. - The distribution segment achieved revenue of RMB 744,814 thousand, resulting in a gross profit of RMB 347,420 thousand[79]. - The technical services segment reported revenue of RMB 190,084 thousand, with a gross profit of RMB 91,231 thousand[79]. - Revenue from ophthalmic medical devices was RMB 641,305 thousand, down from RMB 718,718 thousand in 2021, representing a decline of 10.8%[83]. - Revenue from ophthalmic medical consumables increased slightly to RMB 411,814 thousand from RMB 408,368 thousand, showing a growth of 1.1%[83]. Research and Development - The company has made significant investments in R&D for artificial crystals, OK lenses, ophthalmic surgical consumables, and related equipment, with major breakthroughs in crystal injection molding technology[9]. - The company operates four R&D centers in China and two in Europe (Netherlands and Germany) to expand its self-owned product portfolio[8]. - As of December 31, 2022, the company employed 38 R&D personnel, with an average industry experience of over ten years, enhancing its product development capabilities[10]. - R&D costs increased by 74.8% from RMB 235 million for the year ended December 31, 2021, to RMB 411 million for the year ended December 31, 2022, reflecting the company's commitment to expanding its R&D team and upgrading its R&D center[31]. - The company aims for self-owned product revenue to exceed 50% of total revenue, focusing on increasing R&D investment and enhancing the contribution of self-owned products[20]. Market Expansion and Partnerships - The company has established partnerships with 20 overseas brands, with 16 having exclusive distribution agreements, including Heidelberg, Schwind, and Optos[4]. - The company has established exclusive distribution agreements with 20 overseas brand partners, with products sold in 51 countries and regions[12]. - In March 2023, the company became the exclusive partner for sales and technical services of Haag-Streit Group's diagnostic equipment in mainland China[15]. - The company plans to continue expanding its market presence through strategic acquisitions and partnerships in the medical technology sector[116]. - The company is exploring market expansion opportunities through potential mergers and acquisitions in the medical technology sector[121]. Financial Position and Governance - The company has maintained a stable financial position despite challenges from COVID-19, with sufficient cash flow and resources to support operational needs and expansion plans[19]. - The company did not recommend the distribution of a final dividend for the year ended December 31, 2022[2]. - The company has established an audit committee consisting of two independent non-executive directors and one non-executive director to oversee financial reporting[60]. - The company will continue to review and monitor its corporate governance practices to ensure compliance with the corporate governance code[59]. - The company aims to maintain a strong financial position while pursuing growth opportunities in the medical device industry[116]. Employee and Operational Metrics - The total employee cost for the year ending December 31, 2022, was RMB 288.4 million, with a total of 790 employees[57]. - The company has a diversified customer base, which mitigates the concentration risk associated with trade receivables[106]. - The company is committed to strict credit control measures to minimize credit risk associated with trade receivables[106]. Taxation and Compliance - Income tax expenses increased by 44.8% from RMB 536 million for the year ended December 31, 2021, to RMB 776 million for the year ended December 31, 2022, due to an increase in taxable profits[35]. - The total tax expense for the year ended December 31, 2022, was RMB 77,618,000, compared to RMB 53,607,000 for 2021, representing an increase of approximately 44.7%[97]. - The company's subsidiary in mainland China, Wenzhou Gaoshi Leimeng Optoelectronic Technology Co., Ltd., benefited from a reduced corporate income tax rate of 15% for the years ended December 31, 2021, and 2022 due to its status as a "High-tech Enterprise"[95]. Cash Flow and Liquidity - Cash and cash equivalents increased by 18.5% to RMB 721.5 million as of December 31, 2022, from RMB 609.0 million as of December 31, 2021, due to increased operating cash flow and funds raised from the IPO[45]. - The company had interest-bearing bank and other borrowings of RMB 701.6 million as of December 31, 2022, including short-term borrowings of RMB 131.9 million and long-term borrowings of RMB 569.7 million[45]. - The debt-to-asset ratio was 50.9% as of December 31, 2022, compared to a negative 151.8% as of December 31, 2021, due to the recognition of net liabilities under IFRS[48]. Strategic Focus and Future Outlook - The management provided guidance for future performance, emphasizing a commitment to innovation and market expansion strategies[116]. - The company is focused on developing new products and technologies to enhance its competitive edge in the healthcare market[116]. - The company aims to enhance its research and development efforts to drive innovation in medical devices and treatments[121].